Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
NCT ID: NCT01148108
Last Updated: 2013-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
14 participants
INTERVENTIONAL
2010-06-30
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs
NCT02597387
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients
NCT03141203
Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients
NCT02445248
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
NCT00798096
Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy
NCT02464228
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mantle Cell Lymphoma
Patients with relapsed or refractory mantle cell lymphoma
Canfosfamide HCl for injection
30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
Diffuse Large B Cell Lymphoma
Patients with relapsed or refractory diffuse large B cell lymphoma
Canfosfamide HCl for injection
30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
Multiple Myeloma
Patients with relapsed or refractory multiple myeloma
Canfosfamide HCl for injection
30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Canfosfamide HCl for injection
30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* histologically or cytologically confirmed disease
* characteristic immunophenotypic profiles
* measurable disease (for lymphoma patients)
* ECOG performance status of 0-2
* adequate liver and kidney function
* adequate bone marrow reserves
* ineligible or unwilling to undergo autologous stem cell transplantation
Exclusion Criteria
* pregnant or lactating women
* women of child-bearing potential not using reliable and appropriate contraception
* routine prophylactic use of G-CSF required within 2 weeks of study entry
* Grade 3 or higher peripheral neuropathy
* history of hepatitis B virus or HIV
* central nervous system or meningeal involvement by lymphoma or multiple myeloma
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Telik
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph Bertino, MD
Role: PRINCIPAL_INVESTIGATOR
Rutgers Cancer Institute of New Jersey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TLK286.2030
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.